OncoSec Medical has obtained CE certification for its proprietary gene and drug delivery technology, designed to treat solid tumor cancers.
The assessment and certification process was supervised by SGS Group, a provider of inspection, verification, testing and certification services.
The delivery technology, OncoSec Medical System (OMS) electroporation device, opens the skin pores, by inducing short electric impulses, of tumor’s membrane and increases the uptake of anti-cancer agents.
OncoSec president and CEO Punit Dhillon said the CE certification allows the company to sell the delivery device in the European Economic Area (EEA).
"The CE mark shows that OncoSec has the capability to manufacture and develop a device that meets commercial regulatory requirements," Dhillon added.